NYU Study Links Diverse Cannabis Use Patterns to Heavier Consumption

Multi-Method Users Show Elevated Consumption Across All Categories

The NYU research team found that consumers using three or more cannabis forms reported 40-60% higher weekly consumption than single-method users, even after controlling for frequency of use. The study tracked 2,847 adult cannabis consumers across six months, collecting self-reported data on smoking, vaping, edibles, tinctures, topicals, and concentrates.

Lead researcher Dr. Joseph Palamar noted that diversity of use—not just frequency—emerged as the strongest predictor of total THC intake. A consumer who smokes daily but never uses edibles consumed less THC per week than someone who smoked three times weekly but also vaped and used concentrates.

That pattern held even when researchers isolated for tolerance. The multi-method cohort wasn't simply using more because they'd built higher tolerance. They were selecting different forms for different contexts, stacking consumption across the day.

Edibles and Concentrates Drive the Heaviest Use Profiles

Consumers who combined smoking with edibles and concentrates reported the highest weekly THC intake, averaging 420-580 mg compared to 180-240 mg for flower-only users. The study used self-reported potency estimates cross-checked against state-level testing data from legal markets.

Concentrate users who also consumed edibles showed the steepest escalation curve over the six-month study window. By month six, this cohort's median weekly intake had increased 34%. Flower-only users showed no statistically significant change.

Researchers flagged this as a clinical concern. Edibles deliver delayed, longer-lasting effects; concentrates deliver immediate high-potency hits. Users combining both may be chasing different pharmacological windows throughout the day, a behavior pattern associated with dependence in other substance categories.

Clinical Implications for CUD Screening

The findings suggest current cannabis use disorder screening tools may undercount risk by focusing on frequency rather than method diversity. Standard CUD assessments ask how many days per month a patient consumes cannabis. They rarely ask how many different forms.

Dr. Palamar's team argues that a patient using cannabis 10 days per month across four different methods may present higher risk than someone using 20 days per month via flower alone. The former pattern indicates polysubstance-style behavior within a single drug category.

For context on how use-pattern research informs clinical practice, see the CannIntel topic hub on Cannabis Use Patterns Research.

The study didn't assess whether method diversity predicts worse health outcomes—only that it predicts heavier use. That's the next research question. If heavier use correlates with impairment, dependence, or adverse events, then method diversity becomes a screening red flag.

What This Means for Product-Mix Strategy

For MSOs and dispensaries, the data cuts two ways: multi-method consumers are your highest-revenue customers, but they may also be your highest-risk cohort for regulatory scrutiny. If future research links method diversity to CUD or impaired driving, state regulators could impose purchase limits across categories, not just within them.

California's DCC already tracks per-transaction purchase volumes. It's not hard to imagine a future rule capping combined flower, edible, and concentrate purchases per day, which would hit basket size hard for the 18-22% of consumers the NYU study identified as multi-method users.

The flip side? This cohort is also your loyalty segment. They're not tourists. They're daily users with sophisticated preferences, and if you can't serve their full product mix, they'll split their spend across competitors. The math is brutal.

Watch this next variable: whether insurance carriers or employers start using method-diversity screens in workplace drug policies or health-risk assessments. If they do, the clinical framing of this research will matter as much as the data itself.